22
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: not found

      Safety, efficacy, and biomarkers of nivolumab with vaccine in ipilimumab-refractory or -naive melanoma.

      Read this article at

      ScienceOpenPublisherPMC
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Nivolumab, a human immunoglobulin G4-blocking antibody against the T-cell programmed death-1 checkpoint protein, has activity against metastatic melanoma. Its safety, clinical efficacy, and correlative biomarkers were assessed with or without a peptide vaccine in ipilimumab-refractory and -naive melanoma.

          Related collections

          Author and article information

          Journal
          J Clin Oncol
          Journal of clinical oncology : official journal of the American Society of Clinical Oncology
          American Society of Clinical Oncology (ASCO)
          1527-7755
          0732-183X
          Dec 01 2013
          : 31
          : 34
          Affiliations
          [1 ] Jeffrey S. Weber, Ragini Reiney Kudchadkar, Bin Yu, Donna Gallenstein, Xiuhua Zhao, Alberto J. Martinez, Wenshi Wang, Geoffrey Gibney, Jodi Kroeger, Cabell Eysmans, Amod A. Sarnaik, and Y. Ann Chen, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL; and Christine E. Horak and H. David Inzunza, Bristol-Myers Squibb, Princeton, NJ.
          Article
          JCO.2013.51.4802
          10.1200/JCO.2013.51.4802
          3837092
          24145345
          f985ceaa-8afe-4dab-bb22-5cd056f0c7cd
          History

          Comments

          Comment on this article